Xtant Medical HoldingsXTNT
XTNT
About: Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Employees: 232
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
7% more funds holding
Funds holding: 28 [Q3] → 30 (+2) [Q4]
1.25% less ownership
Funds ownership: 70.81% [Q3] → 69.56% (-1.25%) [Q4]
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
35% less capital invested
Capital invested by funds: $66.1M [Q3] → $42.8M (-$23.3M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for XTNT.
Financial journalist opinion
Based on 5 articles about XTNT published over the past 30 days
Neutral
Seeking Alpha
2 days ago
Xtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brett Maas - Hayden IR Sean Browne - President and Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Ryan Zimmerman - BTIG Operator Good afternoon, everyone, and welcome to the Xtant Medical's First Quarter 2025 Financial Results. At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation.
Neutral
PRNewsWire
2 days ago
Xtant Medical Reports First Quarter 2025 Financial Results
Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont. , May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025.
Neutral
PRNewsWire
1 week ago
Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025
BELGRADE, Mont. , May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025.
Neutral
PRNewsWire
3 weeks ago
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance
BELGRADE, Mont. , April 23, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.(NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, is proud to announce the launch of Trivium™, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures.
Neutral
PRNewsWire
4 weeks ago
Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%
Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont. , April 16, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced the completion of a secondary private sale of 73.1 million shares of Xtant common stock held by funds affiliated with OrbiMed Advisors LLC ("OrbiMed") to several existing and new stockholders, led by Nantahala Capital Management LLC ("Nantahala").
Neutral
Seeking Alpha
2 months ago
Xtant Medical Holdings, Inc. (XTNT) Q4 2024 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q4 2024 Results Conference Call March 6, 2025 4:30 PM ET Company Participants Brett Maas - Hayden IR Sean Browne - President & Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, everyone, and welcome to the Xtant Medical Fourth Quarter and Year-End 2024 Earnings. At this time, all participants have been placed on a listen-only mode.
Neutral
Accesswire
2 months ago
Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS Newswire / March 6, 2025 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2024 and provided full year revenue guidance for 2025. Fourth Quarter 2024 Financial Highlights Revenue of $31.5 million, up 12%, compared to the prior year quarter Gross margin of 50.8% compared to 61.0% for the prior year quarter Net loss of $3.2 million compared to a net loss of $4.3 million in the prior year quarter Adjusted EBITDA of $438,000 compared to Adjusted EBITDA loss of $695,000 in the prior year quarter Full Year 2024 Financial Highlights Revenue of $117.3 million, up 28%, compared to the prior year Gross margin of 58.2% compared to 60.8% for the prior year Net loss of $16.4 million compared to net income of $660,000 in the prior year, which included a $11.7 million bargain purchase gain related to the acquisition of Surgalign Holdings Adjusted EBITDA loss of $2.3 million compared to an Adjusted EBITDA loss of $1.4 million in the prior year Recent Business Highlights Subsequent to year end, in the first quarter of 2025, entered into a two-year manufacture and license agreement with automatic renewals with a distributor granting the right to manufacture and supply Xtant's SimpliGraft® product that provides for an upfront payment of $1.5 million and minimum purchase obligations Reduced operating expenses by more than $5 million on an annualized basis since third quarter of 2024.
Neutral
Accesswire
2 months ago
Xtant Medical to Issue Fourth Quarter and Year End 2024 Financial Results on March 6, 2025
BELGRADE, MT / ACCESS Newswire / February 28, 2025 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2024, after the close of the financial markets on Thursday, March 6, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, March 6, 2025 at 4:30 PM ET to review results.
Neutral
Seeking Alpha
6 months ago
Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Operator Welcome to the Xtant Medical Holdings, Inc. Third Quarter 2024 Conference Call. At this time all participants are in a listen only mode.
Neutral
Accesswire
6 months ago
Xtant Medical Reports Third Quarter 2024 Financial Results
Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year period Gross margin of 58.4% compared to 61.3% for the prior year quarter Net loss of $5.0 million compared to net income of $9.2 million in the prior year quarter which included a $11.0 million bargain purchase gain related to the acquisition of Surgalign Holdings Adjusted EBITDA of $(196,000) compared to $440,000 in the prior year quarter Recent Business Highlights Launched OsteoVive+, a moldable, viable bone matrix for use in a variety of grafting procedures Launched Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries Signed a license agreement for Q-Codes and corresponding SimpliMax Dual Layer Amniotic Membrane, which provides for a minimum of $5.25 million in licensing and royalty fees Completed $5.0 million private placement on August 9, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "During the third quarter, we expanded our market opportunities with the launch of two new products, OsteoVive+ (stem cells) and Cortera Posterior Fixation System.
Charts implemented using Lightweight Charts™